Munro Gordon, Erichsen Helle K, Mirza Naheed R
NeuroSearch A/S, 93 Pederstrupvej, DK-2750, Ballerup, Denmark.
Neuropharmacology. 2007 Oct;53(5):609-18. doi: 10.1016/j.neuropharm.2007.07.002. Epub 2007 Jul 21.
Signs and symptoms of persistent pain are associated with neuronal hyperexcitability within nociceptive pathways. This manifests behaviourally as a decrease in the nociceptive threshold to sensory stimulation, and is closely correlated with altered affective pain processing and increased expression of anxiety-like symptoms. Anticonvulsant drugs can have marked analgesic actions in animals and humans, and some have also been reported to possess anxiolytic-like properties in animals. In the current study, we have compared the antinociceptive actions of diazepam (allosteric GABA(A) receptor modulator), gabapentin (binds to alpha(2)delta Ca(2+) channel subunit), lamotrigine, riluzole and phenytoin (Na(+) channel blockers), levetiracetam (unknown mechanism), sodium valproate (potentiates GABA-mediated inhibition), ethosuximide (T-type Ca(2+) channel blocker) and retigabine (K(v)7 channel opener) in the rat formalin test, with their anxiolytic actions in the rat conditioned emotional response (CER) model of anxiety. Lamotrigine, gabapentin, riluzole, retigabine and ethosuximide attenuated second phase nociceptive responses in the formalin test. Lamotrigine, gabapentin and riluzole also displayed an anxiolytic-like profile in the CER model. Notably, the minimum doses of these drugs required to attenuate anxiety behaviour were similar to, or considerably lower than those needed to reverse pain-like behaviours. Diazepam was anxiolytic but only attenuated pain-like behaviours at sedative doses. The other drugs tested were inactive in both models. Our data suggests: (i) an antiepileptic mechanism of action per se is not necessarily sufficient for a compound to display antinociceptive and/or anxiolytic actions; and (ii) the combined antinociceptive and anxiolytic-like profiles of lamotrigine, gabapentin and riluzole suggests that these compounds likely modulate both sensory and affective dimensions of pain.
持续性疼痛的体征和症状与伤害性感受通路内的神经元兴奋性过高有关。这在行为上表现为对感觉刺激的伤害性感受阈值降低,并且与情感性疼痛处理的改变以及焦虑样症状的表达增加密切相关。抗惊厥药物在动物和人类中可具有显著的镇痛作用,并且据报道一些药物在动物中还具有抗焦虑样特性。在本研究中,我们比较了地西泮(变构GABA(A)受体调节剂)、加巴喷丁(与α(2)δ钙通道亚基结合)、拉莫三嗪、利鲁唑和苯妥英(钠通道阻滞剂)、左乙拉西坦(作用机制不明)、丙戊酸钠(增强GABA介导的抑制作用)、乙琥胺(T型钙通道阻滞剂)和瑞替加滨(K(v)7通道开放剂)在大鼠福尔马林试验中的抗伤害性感受作用,以及它们在大鼠焦虑条件性情绪反应(CER)模型中的抗焦虑作用。拉莫三嗪、加巴喷丁、利鲁唑、瑞替加滨和乙琥胺减弱了福尔马林试验中的第二相伤害性感受反应。拉莫三嗪、加巴喷丁和利鲁唑在CER模型中也表现出抗焦虑样特征。值得注意的是,减弱焦虑行为所需的这些药物的最小剂量与逆转疼痛样行为所需的剂量相似或显著更低。地西泮具有抗焦虑作用,但仅在镇静剂量下减弱疼痛样行为。所测试的其他药物在两个模型中均无活性。我们的数据表明:(i)化合物本身的抗癫痫作用机制不一定足以使其表现出抗伤害性感受和/或抗焦虑作用;(ii)拉莫三嗪、加巴喷丁和利鲁唑的联合抗伤害性感受和抗焦虑样特征表明,这些化合物可能调节疼痛的感觉和情感维度。